Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: Thomson Reuters Stock Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Valeant Pharmaceuticals International Inc reaffirms FY 2014 guidance

Thursday, 27 Feb 2014 06:01am EST 

Valeant Pharmaceuticals International Inc:Reaffirms fiscal 2014 cash EPS guidance of $8.25 to $8.75, which includes overcoming the negative impact from currency fluctuations since the beginning of the year of about $0.10 per share.This guidance does not include the positive impact of the PreCision Dermatology, Inc. acquisition, which is expected to close in the second quarter of 2014.Expects fiscal 2014 total revenue to be in the range of $8.2 billion to $8.6 billion.Fiscal 2014 EPS of $8.64 and revenue of $8.4 billion - Thomson Reuters I/B/E/S.